

Erratum to: Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency

James J. Maciejko^{1,2} 

Published online: 25 March 2017
© Springer International Publishing Switzerland 2017

Erratum to: Am J Cardiovasc Drugs DOI 10.1007/s40256-017-0216-5

Section 6.3, para 5, lines 15–17 which previously read:

The mean percent changes in LDL-C, TG and apo B levels from baseline were –21, –14 and –23%, respectively, in the rhSA-treated group.

Should read:

The mean percent changes in LDL-C, TG and apo B levels compared with placebo were –21, –14 and –23%, respectively, in the rhSA-treated group.

Section 6.3, para 6, lines 1–3 which previously read:

Adverse events were mild and similar in the treated and placebo groups, and included headache (10%), pyrexia (7%), diarrhea (6%), runny nose (4%) and nausea (3%).

Should read:

Adverse events were mild and similar in the treated and placebo groups, and included headache ($n = 10$), pyrexia ($n = 7$), diarrhea ($n = 6$), runny nose ($n = 4$) and nausea ($n = 3$).

The online version of the original article can be found under doi:[10.1007/s40256-017-0216-5](https://doi.org/10.1007/s40256-017-0216-5).

✉ James J. Maciejko
james.maciejko@ascension.org

¹ Division of Cardiology, St. John Hospital and Medical Center, 22101 Moross Road, Detroit, MI 48236, USA

² Department of Internal Medicine, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI 48201, USA